Clinical Trial Results:
A Phase 1b/2, First-in-Human, Dose Escalation and Expansion Study of XMT-1536 In Patients with Solid Tumors Likely to Express NaPi2b
Summary
|
|
EudraCT number |
2020-000630-17 |
Trial protocol |
FR NO LT CZ HU BG FI PL DK IT AT BE |
Global completion date |
|
Paediatric regulatory details
|
|
Is the trial part of an agreed EMA paediatric investigation plan? |
|
Is the trial in scope of article 45 of Regulation (EC) No 1901/2006? |
|
Is the trial in scope of article 46 of Regulation (EC) No 1901/2006? |
|
Results information
|
|
Results version number |
v1(current) |
This version publication date |
05 Jul 2024
|
First version publication date |
05 Jul 2024
|
Other versions |
|
Summary report(s) |
UPLIFT SUMMARY ATTACHMENT for EudraCT Posting |
Note: The legislation allows summary attachments to be posted instead of the full dataset for this trial. Refer to Commission Guideline 2012/C 302/03
for further information.